Overview

* Cellebrite Q2 revenue grows 18% yr/yr, beating analyst expectations, per LSEG data

* Adjusted EBITDA for Q2 beats estimates, reflecting a 29% increase, per LSEG data

* Net income for Q2 misses analyst expectations, per LSEG data

Outlook

* Cellebrite expects Q3 revenue between $121 mln and $126 mln

* Full-year 2025 revenue forecasted at $465 mln to $475 mln

* Company anticipates Q3 adjusted EBITDA of $31 mln to $34 mln

* Full-year adjusted EBITDA expected to be $118 mln to $123 mln

* Pending acquisition of Corellium expected to enhance digital investigation capabilities

Result Drivers

* SUBSCRIPTION REVENUE - Subscription revenue increased 21% yr/yr, contributing to overall revenue growth

* GROSS PROFIT - GAAP gross profit and gross margin of $95.6 million and 84.4%, respectively; Non-GAAP gross profit and gross profit margin of $96.4 million and 85.1%, respectively

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $113.28 $112.20

Revenue mln mln (8

Analysts

)

Q2 Net Miss $19.48 $25.40

Income mln mln (5

Analysts

)

Q2 Beat $27.88 $27 mln

Adjusted mln (7

EBITDA Analysts

)

Q2 Gross 84.4%

Margin

Q2 Cash $32.58

Flow mln

from

Operatin

g

Activiti

es

Q2 $14.42

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the software peer group is "buy"

* Wall Street's median 12-month price target for Cellebrite DI Ltd ( CLBT ) is $24.50, about 42.9% above its August 13 closing price of $13.99

* The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 45 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)